MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study - Archive ouverte HAL Access content directly
Journal Articles Oncotarget Year : 2016

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (14) , (2) , (2) , (2) , (2) , (15) , (16)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Steven van Laere
Naoto Ueno

Dates and versions

hal-03623733 , version 1 (29-03-2022)

Identifiers

Cite

Emeline Tabouret, François Bertucci, Jean-Yves Pierga, Thierry Petit, Christelle Levy, et al.. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget, 2016, 7 (14), pp.18531-18540. ⟨10.18632/oncotarget.7612⟩. ⟨hal-03623733⟩
8 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More